Codexis Inc (CDXS) Stock Price, Quote & News

Company Profile

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with A...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 421 8100

Website: www.codexis.com

Address:

200 Penobscot Drive, Redwood City, United States

Bondra Feb. 3 at 5:22 PM

$CDXS As ive said before - Opaleye has MILLIONS left to sell - that is what you are witnessing. See you at the R/S vote

0 · Reply

Fingerlickengood Feb. 3 at 3:34 PM

$CDXS https://www.diaglobal.org/Tools/Content.aspx?type=eopdf&file=%2fproductfiles%2f15013623%2f26011-cfa%2Epdf

0 · Reply

AnalyticaInvestor Feb. 3 at 12:15 PM

$VTGN $EML $QMCO Good morning, investors. Liquidity and macro signals remain the main drivers as delayed labor data and mixed Fed commentary keep rate expectations fluid. On the watchlist, $QMCO remains deeply discounted after a sharp YTD selloff, with insider buying standing out. $VTGN faces headline risk but has upcoming clinical milestones, while $EML trades near its 52 week low with recent director purchases signaling confidence. Among movers, Mexican hospitality developers jumped +30%, while $TNYA and $CDXS moved higher on healthcare momentum. SPACs stayed under pressure, with several down as much as 26% on thinning liquidity. Bitcoin treasury strategy names saw heavy churn as traders reacted to dilution and balance sheet headlines. Read the full Analytica Alpha 👇 https://analyticainvestor.beehiiv.com/p/delayed-jobs-data-stalls-clarity

0 · Reply

Fingerlickengood Feb. 3 at 12:13 PM

$CDXS https://www.wsj.com/business/earnings/merck-expects-slower-earnings-growth-as-it-spends-on-acquisitions-bb48338f?gaa_at=eafs&gaa_n=AWEtsqdEvwDdS5T6oC7HSKqiGJ6SC0evp_rbPm-FMBCLTQnVBFqsXV7v4USOKzk8CK4%3D&gaa_ts=6981e8f5&gaa_sig=gtGGWUslIla7AnZwDoOFTONFiocuQEIh4f0I51DnA0uzNkfVT8sZ_hjKdhW6PfA1ScmGNeZX9fTj4O9Cz8Ibxw%3D%3D

1 · Reply

StockScanners Feb. 3 at 3:40 AM

$CDXS keep watch if this holds above 1.40

0 · Reply

Fingerlickengood Feb. 3 at 2:02 AM

$CDXS it went to $1.45 and people think it’s bullish!

0 · Reply

Fingerlickengood Feb. 2 at 9:19 PM

$CDXS Im interested in what $MRK might disclose tomorrow Am! https://seekingalpha.com/news/4545719-merck-q4-2025-earnings-preview

1 · Reply

Bondra Feb. 2 at 5:39 PM

$CDXS Opaleye took the day off

0 · Reply

Camille65 Feb. 2 at 5:38 PM

$CDXS relevant to Codexis ECO platform "US FDA launches program to boost domestic drug manufacturing" "The FDA said it would select an initial group of new pharmaceutical manufacturing facilities this year based on "alignment with national priorities" in several areas including the product itself, how quickly it can be developed for the U.S. market, and innovations in facility development." ""Additional priority considerations will be given to facilities producing critical medications for the U.S. market," the agency said in a statement." https://www.reuters.com/sustainability/boards-policy-regulation/us-fda-launches-program-boost-domestic-drug-manufacturing-2026-02-01/

1 · Reply

buymoremakemore Feb. 2 at 5:24 PM

$CDXS 😉

0 · Reply

Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics

Nov 10, 2025, 9:00 AM EST - 3 months ago

Codexis Announces Signing of Lease for GMP Manufacturing Facility

Nov 7, 2025, 2:16 PM EST - 3 months ago

Codexis, Inc. (CDXS) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 9:58 AM EDT - 3 months ago

Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing

Oct 23, 2025, 7:05 AM EDT - 3 months ago

Codexis to Report Third Quarter 2025 Financial Results on November 6

Aug 28, 2025, 9:00 AM EDT - 5 months ago

Codexis to Participate in Cantor Global Healthcare Conference

Aug 13, 2025, 7:57 PM EDT - 6 months ago

Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:05 PM EDT - 6 months ago

Codexis Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 6 months ago

Codexis to Report Second Quarter 2025 Financial Results on August 13

May 22, 2025, 7:00 AM EDT - 9 months ago

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

May 21, 2025, 4:05 PM EDT - 9 months ago

Codexis to Participate in Jefferies Global Healthcare Conference

May 14, 2025, 6:50 PM EDT - 9 months ago

Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:05 PM EDT - 9 months ago

Codexis Reports First Quarter 2025 Financial Results

May 7, 2025, 7:00 AM EDT - 9 months ago

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

Apr 30, 2025, 4:05 PM EDT - 9 months ago

Codexis to Report First Quarter 2025 Financial Results on May 14

Apr 9, 2025, 5:00 PM EDT - 10 months ago

Codexis Announces Byron Dorgan to Retire from Board of Directors

Mar 7, 2025, 4:05 PM EST - 11 months ago

Codexis Announces New Employment Inducement Grants

Feb 27, 2025, 10:20 PM EST - 1 year ago

Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 4:05 PM EST - 1 year ago

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

Feb 6, 2025, 4:05 PM EST - 1 year ago

Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

Jan 16, 2025, 4:05 PM EST - 1 year ago

Codexis Appoints Christos Richards to Board of Directors

Nov 19, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:05 PM EST - 1 year ago

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

Nov 12, 2024, 4:05 PM EST - 1 year ago

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors

Nov 11, 2024, 4:05 PM EST - 1 year ago

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Nov 4, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Upcoming Healthcare Conferences

Oct 31, 2024, 10:48 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 4:05 PM EDT - 1 year ago

Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting

Oct 10, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report Third Quarter 2024 Financial Results on October 31

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company

Oct 1, 2024, 7:05 AM EDT - 1 year ago

Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences

Aug 20, 2024, 4:05 PM EDT - 1 year ago

Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Codexis Publishes FY2023 Sustainability Disclosures

Aug 8, 2024, 11:01 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report Second Quarter 2024 Financial Results on August 8

Jul 1, 2024, 4:05 PM EDT - 1 year ago

Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets

May 20, 2024, 4:05 PM EDT - 1 year ago

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

May 14, 2024, 6:00 AM EDT - 1 year ago

Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting

May 2, 2024, 8:24 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript

Apr 18, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report First Quarter 2024 Financial Results on May 2

Apr 11, 2024, 7:05 AM EDT - 1 year ago

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Feb 28, 2024, 10:39 PM EST - 2 years ago

Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 4:05 PM EST - 2 years ago

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 26, 2024, 4:05 PM EST - 2 years ago

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

Feb 26, 2024, 8:05 AM EST - 2 years ago

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

Feb 20, 2024, 8:05 AM EST - 2 years ago

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Feb 14, 2024, 4:05 PM EST - 2 years ago

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

Feb 13, 2024, 4:05 PM EST - 2 years ago

Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones

Feb 1, 2024, 4:05 PM EST - 2 years ago

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

Dec 27, 2023, 8:30 AM EST - 2 years ago

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Bondra Feb. 3 at 5:22 PM

$CDXS As ive said before - Opaleye has MILLIONS left to sell - that is what you are witnessing. See you at the R/S vote

0 · Reply

Fingerlickengood Feb. 3 at 3:34 PM

$CDXS https://www.diaglobal.org/Tools/Content.aspx?type=eopdf&file=%2fproductfiles%2f15013623%2f26011-cfa%2Epdf

0 · Reply

AnalyticaInvestor Feb. 3 at 12:15 PM

0 · Reply

Fingerlickengood Feb. 3 at 12:13 PM

1 · Reply

StockScanners Feb. 3 at 3:40 AM

$CDXS keep watch if this holds above 1.40

0 · Reply

Fingerlickengood Feb. 3 at 2:02 AM

$CDXS it went to $1.45 and people think it’s bullish!

0 · Reply

Fingerlickengood Feb. 2 at 9:19 PM

$CDXS Im interested in what $MRK might disclose tomorrow Am! https://seekingalpha.com/news/4545719-merck-q4-2025-earnings-preview

1 · Reply

Bondra Feb. 2 at 5:39 PM

$CDXS Opaleye took the day off

0 · Reply

Camille65 Feb. 2 at 5:38 PM

1 · Reply

buymoremakemore Feb. 2 at 5:24 PM

$CDXS 😉

0 · Reply

10xMoonstocks Feb. 2 at 4:35 PM

$CDXS @fingerlickegood looks like you were a litte off....Maybe you can flip back to a bull now. Haha!

1 · Reply

Camille65 Jan. 31 at 12:53 PM

$CDXS

0 · Reply

Jdnguyen24 Jan. 30 at 8:58 PM

$CDXS Continue to feel the frustration on more concrete info for time being Longs. Earnings calls & healthcare conferences all last year, they’re not comfortable to name clients they are signing up with concern on competition to a degree as of yet, but I suspect once there is a larger scale of sIRNA therapeutics into Phase 3/4 in the market, they’ll have a better clarity on where their Eco-Platform fits within the sIRNA Eco-System, patience is all we got. Dilly did say CDXS will be willing to provide value of signed contracts in tandem with the types of product being sold. 2026 is major transformative year but yes, tough on the waiting, but revenue, revenue is their one inevitable show me they will have to disclose. GL Longs!🥃

0 · Reply

buymoremakemore Jan. 30 at 8:41 PM

$CDXS at least bleeding much slower tofay

0 · Reply

Jdnguyen24 Jan. 30 at 6:49 PM

$CDXS I’ve owned them for 8yrs in/out, they have always been transparent on their financials, no accounting tricks etc. It’s a bummer Bio-Tech has always taken longer, but it’s also context, there are only ~7 approved sIRNA therapeutics commercialized on market? ~400 in pipeline at all phases? If Pharma companies who’ve used phosphorite chemistry model, they know if they opt-into Eco, there is no going back. It’s too expensive of a hassle to go back etc. It’s big $ at stake, so of course they’re going to take their 🤬 time🤣 They don’t give a 💩 about investor’s timeline. It’s either you buy into their vision which I do or politely dump shares & move on. It’s why CDXS double strand Ligase is such a critical product as the bridge to Eco. Pharma wants a proof of concept each baby step of the way.

1 · Reply

Camille65 Jan. 30 at 6:29 PM

$CDXS This is the third consecutive Friday in January (16th, 23rd and 30th) with the same trading patter; slowly and gradully push it down, smack any uptick and pull the rug underneath. Shorts/bears want to spread maximum fear, so work to "manipulate" hard down by closing and leave anxiety during the weekend. With the absence of news/catalysts, this tactis may carry on and everyday's low turns to be false bottom. Manipulative trading

2 · Reply

Fingerlickengood Jan. 30 at 6:21 PM

$CDXS Another thing I've noted is that none of these companies Codexis has done research with over the past year and completed joint presentations with has provided any financial backing to future licensing. Why not? They said eight months ago they had multiple companies (40 I believe) that had reached out and were looking at their technology and discussion on licencing. Not one has made a financial commitment since then? VERY Odd!

2 · Reply

Fingerlickengood Jan. 30 at 5:36 PM

$CDXS I foresee a buyout offer on the table yet to be disclosed and Opaleye got wind of it. Somewhere in the $2 range. Will be a sad ending if that is what transpires. Fits with the exit of Dilly, lack of transparency by the company to investors, 25% staff reduction and overall general malaise.

3 · Reply

Bondra Jan. 30 at 4:16 PM

$CDXS Will problably load more at 0.5$.

0 · Reply

Jdnguyen24 Jan. 30 at 4:11 PM

$CDXS Market has had an over reaction pullback on bio-tech and small cap indexes this week. Still staying put & 💪 on Long hold with no fundamental changes. ~2/26/26 Q4 earnings release.

1 · Reply

10xMoonstocks Jan. 29 at 4:44 PM

$CDXS You may have picked the wrong time to flip from bull to bear. Seems like $1.40 is a little more in play than $.40 at the moment

1 · Reply

10xMoonstocks Jan. 29 at 4:22 PM

$CDXS I'm not quite willing to call this the bottom and buy a bunch of shares, but holding today while the market is a blood bath is quite interesting. Is the bottom in? We'll know over the next few days, but this is a much better performance today so far than expected

1 · Reply

Market Cap	112.00M
Revenue (ttm)	59.35M
Net Income (ttm)	-65.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-109.99%
Debt to Equity Ratio	1.03

Volume	983,900
Avg Vol	1,021,336
Day's Range	N/A - N/A
Shares Out	90.32M
Stochastic %K	21%
Beta	2.44
Analysts	Strong Sell
Price Target	$6.58